Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial

被引：0
|
作者：
Marzieh Nojomi
Zeynab Yassin
Hossein Keyvani
Mahin Jamshidi Makiani
Maryam Roham
Azadeh Laali
Nasir Dehghan
Mehrnaz Navaei
Mitra Ranjbar
机构：
[1] Iran University of Medical Sciences,Preventive Medicine & Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine
[2] Iran University of Medical Sciences,Antimicrobial Resistance Research Center, Department of Infectious Disease, School of Medicine, Hazrat
[3] Iran University of Medical Sciences,e Rasool General Hospital
[4] Iran University of Medical Sciences,Department of Virology, School of Medicine, Gastrointestinal and Liver Disease Research Center
[5] Iran University of Medical Sciences,Antimicrobial Resistance Research Center
[6] Iran University of Medical Sciences,Department of Infectious Disease, School of Medicine, Firoozgar General Hospital
[7] Iran University of Medical Sciences,Department of Community and Family Medicine, School of Medicine
来源：
BMC Infectious Diseases | / 20卷
关键词：
Arbidol; Corona virus; COVID-19; Efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
    Nojomi, Marzieh
    Yassin, Zeynab
    Keyvani, Hossein
    Makiani, Mahin Jamshidi
    Roham, Maryam
    Laali, Azadeh
    Dehghan, Nasir
    Navaei, Mehrnaz
    Ranjbar, Mitra
    [J]. BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [2] Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
    Darazam, Ilad Alavi
    Shokouhi, Shervin
    Mardani, Masoud
    Pourhoseingholi, Mohamad Amin
    Rabiei, Mohammad Mahdi
    Hatami, Firouze
    Shabani, Minoosh
    Moradi, Omid
    Gharehbagh, Farid Javandoust
    Irvani, Seyed Sina Naghibi
    Amirdosara, Mahdi
    Hajiesmaeili, Mohammadreza
    Rezaei, Omidvar
    Khoshkar, Ali
    Lotfollahi, Legha
    Gachkar, Latif
    Dehbsneh, Hadiseh Shabanpour
    Khalili, Negar
    Soleymaninia, Azam
    Kusha, Akram Hoseyni
    Shoushtari, Maryam Taleb
    Torabinavid, Parham
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [3] A trial of arbidol hydrochloride in adults with COVID-19
    Zhao Jingya
    Zhang Jinnong
    Jin Yang
    Tang Zhouping
    Hu Ke
    Sun Hui
    Shi Mengmeng
    Yang Qingyuan
    Gu Peiyu
    Guo Hongrong
    Li Qi
    Zhang Haiying
    Li Chenghong
    Yang Ming
    Xiong Nian
    Dong Xuan
    Xu Juanjuan
    Lin Fan
    Wang Tao
    Yang Chao
    Huang Bo
    Zhang Jingyi
    Chen Shi
    He Qiong
    Zhou Min
    Qu Jieming
    [J]. 中华医学杂志(英文版), 2022, 135 (13) : 1531 - 1538
  • [4] A trial of arbidol hydrochloride in adults with COVID-19
    Zhao, Jingya
    Zhang, Jinnong
    Jin, Yang
    Tang, Zhouping
    Hu, Ke
    Sun, Hui
    Shi, Mengmeng
    Yang, Qingyuan
    Gu, Peiyu
    Guo, Hongrong
    Li, Qi
    Zhang, Haiying
    Li, Chenghong
    Yang, Ming
    Xiong, Nian
    Dong, Xuan
    Xu, Juanjuan
    Lin, Fan
    Wang, Tao
    Yang, Chao
    Huang, Bo
    Zhang, Jingyi
    Chen, Shi
    He, Qiong
    Zhou, Min
    Qu, Jieming
    [J]. CHINESE MEDICAL JOURNAL, 2022, 135 (13) : 1531 - 1538
  • [5] Effect of umifenovir (arbidol) versus standard care on clinical outcome in patients with COVID-19: a retrospective cohort study
    Yi, Wanwan
    Jia, Chengyou
    Yang, Ziyu
    Fan, Hengwei
    Li, Ming
    Lv, Zhongwei
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2023, 17
  • [6] Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis
    Amani, Behnam
    Amani, Bahman
    Zareei, Sara
    Zareei, Mahsa
    [J]. IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1197 - 1208
  • [7] Antiviral drug Umifenovir (Arbidol) in municipal wastewater during the COVID-19 pandemic: Estimated levels and transformation
    Ul'yanovskii, Nikolay, V
    Kosyakov, Dmitry S.
    Sypalov, Sergey A.
    Varsegov, Ilya S.
    Shavrina, Irina S.
    Lebedev, Albert T.
    [J]. SCIENCE OF THE TOTAL ENVIRONMENT, 2022, 805
  • [8] Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
    Li, Yueping
    Xie, Zhiwei
    Lin, Weiyin
    Cai, Weiping
    Wen, Chunyan
    Guan, Yujuan
    Mo, Xiaoneng
    Wang, Jian
    Wang, Yaping
    Peng, Ping
    Chen, Xudan
    Hong, Wenxin
    Xiao, Guangming
    Liu, Jinxin
    Zhang, Lieguang
    Hu, Fengyu
    Li, Feng
    Zhang, Fuchun
    Deng, Xilong
    Li, Linghua
    [J]. MED, 2020, 1 (01): : 105 - +
  • [9] Beneficial effect of Arbidol in the management of COVID-19 infection
    Xiong Jie
    Yuan Hongmei
    Fan Ping
    Zhu Kuikui
    Yang Bohan
    Meng Rui
    [J]. AGING-US, 2021, 13 (07): : 9253 - 9264
  • [10] Comparison the Effect of Arbidol Plus Hydroxychloroquine vs Hydroxychloroquine Alone in Treatment of COVID-19 Disease: A Randomized Clinical Trial
    Khodashahi, Rozita
    Naderi, Hamidreza
    Bojdy, Amin
    Heydari, Ali Akbar
    Sani, Ashraf Tavanaee
    Ghabouli, Mohammad Javad
    Sarvghad, Mohammad Reza
    Nateghi, Mahboubeh Haddad
    Arian, Mahnaz
    Jahanian, Shahrzad
    Mazidi, Saeedeh
    Pasand, Maziar Mortazavi
    Hoseini, Binyamin
    Dadgarmoghaddam, Maliheh
    Khorsand, Ali
    Khodashahi, Mandana
    [J]. CURRENT RESPIRATORY MEDICINE REVIEWS, 2020, 16 (04) : 252 - 262
12345